ADMA Biologics to Announce Third Quarter Financial Results
ADMA Biologics, Inc. (NASDAQ: ADMA), a prominent end-to-end commercial biopharmaceutical company, is gearing up to report its financial results for the third quarter of 2024. This important announcement will take place after the U.S. financial markets close, set for November 7, 2024. The management team will also engage with investors during a live conference call, scheduled for 4:30 p.m. ET, where they will not only discuss financial results but also share other significant updates regarding the company.
Joining the Conference Call
Participants who wish to join the conference call can dial (888) 596-4144 and reference conference ID 2959956. It’s suggested that you log in approximately 10 minutes before the call begins. If you prefer, you may listen to the live audio webcast, which will be available on the company's website. For those who can’t attend the live session, an archived replay will be accessible under the "Events & Webcasts" section afterward.
Understanding ADMA Biologics
Established with a mission to address unmet medical needs, ADMA Biologics focuses on the manufacturing, marketing, and development of specialty biologics. The company specializes in products that aid immunodeficient patients who are at increased risk of infections. Its current product line includes three FDA-approved plasma-derived biologics: BIVIGAM® for primary humoral immunodeficiency, ASCENIV™ which is also for primary immunodeficiency, and NABI-HB® that offers enhanced immunity against hepatitis B virus.
Production and Marketing Capabilities
ADMA prides itself on its state-of-the-art manufacturing processes, which are executed at its FDA-licensed facility for plasma fractionation and purification located in Boca Raton, Florida. This facility ensures that the manufacturing of immune globulin products adheres to the highest standards and regulations. Furthermore, through its subsidiary, ADMA BioCenters, the company serves as an FDA-approved source plasma collector in the U.S., securing the plasma needed for product creation directly from donors. This integrated model supports sustainability in ADMA's operations and product supply chain.
Market Position and Innovation
ADMA Biologics is committed to advancing its portfolio, constantly seeking innovations that will not only benefit patients but also expand its market presence. The company is protected by numerous U.S. and international patents that cover various aspects of its existing and potential products. This strong intellectual property foundation presents a robust competitive advantage and signifies ADMA’s commitment to research and development in the biopharmaceutical sector.
Future Commitments
Looking forward, ADMA Biologics aims to continue its trajectory of growth and innovation by introducing new treatments that cater to the distinct needs of niche patient populations suffering from immune deficiencies or those at risk for other infections. The company's focus on specialty biologics positions it uniquely in the market, poised to respond effectively to evolving healthcare challenges. Keeping up with advancements in medical science is essential for ADMA as it strives to enhance its product offerings and improve patient outcomes.
Frequently Asked Questions
What is the purpose of the upcoming financial report?
The financial report aims to provide insight into ADMA Biologics' performance during the third quarter of 2024, including revenue and growth metrics.
How can I listen to the conference call?
You can dial (888) 596-4144 and use conference ID 2959956 to join the call or listen via the company’s website for the live webcast.
What products does ADMA Biologics manufacture?
ADMA Biologics manufactures several FDA-approved biologics, including BIVIGAM®, ASCENIV™, and NABI-HB®, focusing on treatments for immune deficiencies.
Where is ADMA's manufacturing facility located?
The company’s manufacturing facility is located in Boca Raton, Florida, where it conducts plasma fractionation and purification.
What markets does ADMA serve?
ADMA primarily serves immunodeficient patient populations, focusing on specialty biologics to treat and prevent infectious diseases.
